{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T09:49:53Z","timestamp":1695894593432},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Comput Assist Tomogr"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>The purpose of this article is to provide a primer for radiologists outlining the modern systemic therapies used in melanoma brain metastases, including tyrosine kinase inhibitors and immune checkpoint inhibitors. The role of radiologic treatment response evaluation will be discussed from the standpoint of both modern systemic therapies and more traditional treatments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Understanding the role of systemic treatments in melanoma brain metastases is critical for oncologic imaging interpretation in this unique patient population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rct.0000000000001006","type":"journal-article","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T22:55:03Z","timestamp":1585263303000},"page":"346-355","source":"Crossref","is-referenced-by-count":1,"title":["Systemic Therapies for Melanoma Brain Metastases: A Primer for Radiologists"],"prefix":"10.1097","volume":"44","author":[{"given":"Cassidy","family":"Dodson","sequence":"first","affiliation":[{"name":"Department of Radiology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler J.","family":"Richards","sequence":"additional","affiliation":[{"name":"Department of Radiology and Imaging Sciences, University of Utah Hospital, Salt Lake City, UT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert R.","family":"Devita","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Hoimes","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Hematology and Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil H.","family":"Ramaiya","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,3,26]]},"reference":[{"key":"bib1-20230927","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11060-019-03171-6","article-title":"Survival and prognostic factors in surgically treated brain metastases","volume":"143","year":"2019","journal-title":"J Neurooncol"},{"key":"bib2-20230927","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","article-title":"Determinants of outcome in melanoma patients with cerebral metastases","volume":"22","year":"2004","journal-title":"J Clin Oncol"},{"key":"bib3-20230927","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12885-018-4374-x","article-title":"Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies","volume":"18","year":"2018","journal-title":"BMC Cancer"},{"key":"bib4-20230927","first-page":"147","article-title":"Treatment of patients with brain metastases from a melanoma","volume":"23","year":"2019","journal-title":"Cancer Radiother"},{"key":"bib5-20230927","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma","volume":"18","year":"2012","journal-title":"Clin Cancer Res"},{"key":"bib6-20230927","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/annonc\/mdy185","article-title":"Advances in the systemic treatment of melanoma brain metastases","volume":"29","year":"2018","journal-title":"Ann Oncol"},{"key":"bib7-20230927","doi-asserted-by":"crossref","first-page":"9519","DOI":"10.3390\/ijms15069519","article-title":"Molecular biology of brain metastasis","volume":"15","year":"2014","journal-title":"Int J Mol Sci"},{"key":"bib8-20230927","first-page":"4170","article-title":"Molecular and cellular stratagem of brain metastases associated with melanoma","volume":"17","year":"2019","journal-title":"Oncol Lett"},{"key":"bib9-20230927","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.canrad.2014.11.008","article-title":"Imagerie des m\u00e9tastases c\u00e9r\u00e9brales","volume":"19","year":"2015","journal-title":"Cancer Radiother"},{"key":"bib10-20230927","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1148\/radiology.165.1.3628773","article-title":"Intracerebral malignant melanoma: high-field-strength MR imaging","volume":"165","year":"1987","journal-title":"Radiology"},{"key":"bib11-20230927","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","year":"2009","journal-title":"Eur J Cancer"},{"key":"bib12-20230927","first-page":"637","article-title":"Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases","volume":"5","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"bib13-20230927","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1055\/s-0038-1627468","article-title":"Imaging criteria in Neuro-oncology","volume":"38","year":"2018","journal-title":"Semin Neurol"},{"key":"bib14-20230927","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","year":"2015","journal-title":"Lancet Oncol"},{"key":"bib15-20230927","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1602\/neurorx.2.1.86","article-title":"Blood-brain barrier active efflux transporters: ATP-binding cassette gene family","volume":"2","year":"2005","journal-title":"NeuroRx"},{"key":"bib16-20230927","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/jnci\/djt276","article-title":"Selective permeabilization of the blood-brain barrier at sites of metastasis","volume":"105","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"bib17-20230927","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11940-019-0548-3","article-title":"Stereotactic radiosurgery for multiple brain metastases","volume":"21","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"bib18-20230927","first-page":"1","article-title":"The role of surgical resection in patients with brain metastases","volume":"7","year":"2013","journal-title":"Ecancermedicalscience"},{"key":"bib19-20230927","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3171\/jns.1993.79.2.0210","article-title":"Surgical treatment of multiple brain metastases","volume":"79","year":"1993","journal-title":"J Neurosurg"},{"key":"bib20-20230927","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10140-018-1647-2","article-title":"Post-operative complications of craniotomy and craniectomy","volume":"26","year":"2019","journal-title":"Emerg Radiol"},{"key":"bib21-20230927","first-page":"1","article-title":"Immunotherapy in non-metastatic non\u2013small cell lung cancer","volume":"11","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"bib22-20230927","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40425-017-0282-x","article-title":"Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment","volume":"5","year":"2017","journal-title":"J Immunother Cancer"},{"key":"bib23-20230927","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40257-018-0346-9","article-title":"Melanoma brain metastases: local therapies, targeted therapies, immune checkpoint inhibitors and their combinations\u2014chances and challenges","volume":"19","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"bib24-20230927","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/2278-330X.149927","article-title":"Simultaneous integrated boost with intensity modulated radiation therapy in brain oligometastases: a feasible technique for developing countries","volume":"4","year":"2015","journal-title":"South Asian J Cancer"},{"key":"bib25-20230927","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"bib26-20230927","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11060-019-03265-1","article-title":"Single-fraction versus hypofractionated stereotactic radiosurgery for medium-sized brain metastases of 2.5 to 3 cm","volume":"145","year":"2019","journal-title":"J Neurooncol"},{"key":"bib27-20230927","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11912-019-0817-z","article-title":"Neoadjuvant stereotactic radiosurgery: a further evolution in the management of brain metastases","volume":"21","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"bib28-20230927","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1200\/JCO.2015.60.9503","article-title":"Treatment of brain metastases","volume":"33","year":"2015","journal-title":"J Clin Oncol"},{"key":"bib29-20230927","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.2014.57.2909","article-title":"Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib30-20230927","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/COC.0b013e31824be246","article-title":"ACR Appropriateness Criteria\u00ae follow-up and retreatment of brain metastases","volume":"35","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"bib31-20230927","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2217\/fon.13.271","article-title":"Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression?","volume":"10","year":"2014","journal-title":"Future Oncol"},{"key":"bib32-20230927","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.4103\/2152-7806.111301","article-title":"Whole brain radiotherapy for brain metastasis","volume":"4","year":"2013","journal-title":"Surg Neurol Int"},{"key":"bib33-20230927","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.3174\/ajnr.A2668","article-title":"A comprehensive review of MR imaging changes following radiosurgery to 500 brain metastases","volume":"32","year":"2011","journal-title":"AJNR Am J Neuroradiol"},{"key":"bib34-20230927","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/jmri.26171","article-title":"Pseudoprogression of brain tumors","volume":"48","year":"2018","journal-title":"J Magn Reson Imaging"},{"key":"bib35-20230927","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11060-010-0365-8","article-title":"Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis","volume":"103","year":"2011","journal-title":"J Neurooncol"},{"key":"bib36-20230927","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1634\/theoncologist.2014-0012","article-title":"A retrospective evaluation of vemurafenib as treatment for BRAF-mutant melanoma brain metastases","volume":"20","year":"2015","journal-title":"Oncologist"},{"key":"bib37-20230927","first-page":"949","article-title":"Mutations of the BRAF gene in human cancer","year":"2002","journal-title":"Nature"},{"key":"bib38-20230927","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","year":"2012","journal-title":"Lancet"},{"key":"bib39-20230927","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","year":"2012","journal-title":"Lancet Oncol"},{"key":"bib40-20230927","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","year":"2017","journal-title":"Lancet Oncol"},{"key":"bib41-20230927","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejca.2013.11.002","article-title":"Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study","volume":"50","year":"2014","journal-title":"Eur J Cancer"},{"key":"bib42-20230927","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/annonc\/mdw641","article-title":"Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study","volume":"28","year":"2017","journal-title":"Ann Oncol"},{"key":"bib43-20230927","first-page":"1","article-title":"Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma","volume":"21","year":"2017","journal-title":"Contemp Oncol (Pozn)"},{"key":"bib44-20230927","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","year":"2012","journal-title":"Lancet Oncol"},{"key":"bib45-20230927","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1470-2045(12)70324-8","article-title":"Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial","volume":"13","year":"2012","journal-title":"Lancet Oncol"},{"key":"bib46-20230927","doi-asserted-by":"crossref","first-page":"8239","DOI":"10.2147\/OTT.S152514","article-title":"Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies","volume":"11","year":"2018","journal-title":"Onco Targets Ther"},{"key":"bib47-20230927","first-page":"1","article-title":"Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti\u2013PD-1 in patients with metastatic melanoma","year":"2019","journal-title":"Cancer"},{"key":"bib48-20230927","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non\u2013small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"bib49-20230927","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"bib50-20230927","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11912-018-0722-x","article-title":"Pseudoprogression of melanoma brain metastases","volume":"20","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"bib51-20230927","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncponc1183","article-title":"CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS","volume":"5","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"bib52-20230927","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1158\/2326-6066.CIR-15-0160","article-title":"Melanoma brain metastasis pseudoprogression after pembrolizumab treatment","volume":"4","year":"2016","journal-title":"Cancer Immunol Res"}],"container-title":["Journal of Computer Assisted Tomography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RCT.0000000000001006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T18:22:35Z","timestamp":1695838955000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RCT.0000000000001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,26]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rct.0000000000001006","relation":{},"ISSN":["1532-3145","0363-8715"],"issn-type":[{"value":"1532-3145","type":"electronic"},{"value":"0363-8715","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,26]]}}}